It is made available under a CC-BY-NC-ND 4.0 International license .

I. TITLE PAGE 1

Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults 2 **During Delta Versus Omicron Waves** 3

- Margaret K. Doll, PhD, MPH*,^a, Alpana Waghmare, MD*,^{b,c}, Antje Heit, MD, PhD^d, 4
- Brianna Levenson Shakoor, BS^e, Louise E. Kimball, PhD^c, Nina Ozbek, BS^c, Rachel L. 5
- Blazevic, BS^c, Larry Mose, BS^c, Jim Boonyaratanakornkit, MD, PhD^c, Terry L. Stevens-6
- Ayers, MS^c, Kevin Cornell, MS^f, Benjamin D. Sheppard, BS^f, Emma Hampson, BS^f, 7
- Faria Sharmin, MPH^a, Benjamin Goodwin, BS^e, Jennifer M. Dan, MD, PhD^{e,g}, Tom 8
- Archie, MD^f, Terry O'Connor, MD^{f,h}, David Heckerman, MD, PhD^d, Frank Schmitz, MD, PhD^d, Michael Boeckh, MD, PhD^{+,c,i}, Shane Crotty, PhD^{+,e,g} 9
- 10
- *these authors contributed equally as co-first authors 11
- ⁺these authors contributed equally as co-senior authors 12
- ^aDepartment of Population Health Sciences, Albany College of Pharmacy & Health 13
- Sciences, Albany, NY, USA 14
- ^bDivision of Infectious Diseases, Department of Pediatrics, University of Washington, 15
- Seattle, WA, USA 16
- ^cVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 17 18 USA
- ^dAmazon, Inc., Seattle, WA, USA 19
- ^eCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 20 La Jolla, California, USA 21
- ¹St. Luke's Medical Center, Ketchum, ID, USA 22
- 23 ⁹Division of Infectious Diseases and Global Public Health, Department of Medicine,
- University of California, San Diego, La Jolla, California, USA 24
- ^hDepartment of Emergency Medicine, University of Washington, Seattle, WA, USA 25
- ¹Division of Allergy and Infectious Diseases, Department of Medicine, University of 26
- 27 Washington, Seattle, WA, USA
- 28
- 29 Corresponding author: Margaret K. Doll, PhD, MPH; Albany College of Pharmacy &
- Health Sciences, 106 New Scotland Ave, HAB121A, Albany, NY 12208 Phone: 30
- 518.694.7731 Email: margaret.doll@acphs.edu 31
- 32
- Article Type: Original Investigation 33
- Word Count: 2,971 of max 3,000 words 34
- Figures/Tables: 5 of max 5 35
- 36
- 37

It is made available under a CC-BY-NC-ND 4.0 International license .

38 **KEY POINTS** (100 of max 75-100 words or less)

39 **Question:** What are acute and post-acute outcomes among previously uninfected and

40 unvaccinated adults who contracted Omicron (BA.1/BA.2), and how do these compare 41 with Delta infections?

Findings: In this prospective cohort of 274 immunologically naïve adults, 166 (61%)
contracted SARS-CoV-2, with 9 (5.5%) asymptomatic infections. Compared with Delta,
Omicron infections experienced a 79% relative reduction in healthcare utilization, and
56% and 79% relative reductions in the risk and rate of post-acute symptoms (≥5weeks), respectively.

47 Meaning: These findings suggest among immunologically naïve adults, few infections
 48 are asymptomatic, and relative to Delta, Omicron infections have lower likelihoods of
 49 severe illness and post-acute symptoms.

It is made available under a CC-BY-NC-ND 4.0 International license .

52 **II. ABSTRACT** (342 of max 350 words)

- ⁵³ **Importance:** The U.S. arrival of the Omicron variant led to a rapid increase in SARS-
- 54 CoV-2 infections. While numerous studies report characteristics of Omicron infections
- among vaccinated individuals and/or persons with a prior history of infection,
- comprehensive data describing infections among immunologically naïve adults is
 lacking.
- 58
- 59 **Objective:** To examine COVID-19 acute and post-acute clinical outcomes among a
- 60 well-characterized cohort of unvaccinated and previously uninfected adults who
- contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare
- outcomes with infections that occurred during the Delta wave.
- Design: A prospective cohort undergoing high-resolution symptom and virologic
 monitoring between June 2021 and September 2022
- 65 Setting: Multisite recruitment of community-dwelling adults in 8 U.S. states
- 66 **Participants:** Healthy, unvaccinated adults between 30 to 64 years of age without an
- immunological history of SARS-CoV-2 who were at high-risk of infection were recruited.
- 68 Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom
- 69 surveys and nasal swabs for SARS-CoV-2 PCR testing.
- 70 **Exposure(s):** Omicron (BA.1/BA.2 lineages) versus Delta SARS-CoV-2 infection,
- 71 defined as a positive PCR that occurred during a period when the variant represented 72 \geq 50% of circulating SARS-CoV-2 variants in the participant's geographic region.
- 73 Main Outcome(s) and Measure(s): The main outcomes examined were the
- prevalence and severity of acute (\leq 28 days post-onset) and post-acute (\geq 5 weeks postonset) symptoms.
- Results: Among 274 immunologically naïve participants, 166 (61%) contracted SARS-76 CoV-2. Of these, 137 (83%) and 29 (17%) infections occurred during the Omicron- and 77 Delta-predominant periods, respectively. Asymptomatic infections occurred among 78 6.7% (95% CI: 3.1%, 12.3%) of Omicron cases and 0.0% (95% CI: 0.0%, 11.9%) of 79 Delta cases. Healthcare utilization among Omicron cases was 79% (95% CI: 43%, 92%, 80 P = 0.001) lower relative to Delta cases. Relative to Delta, Omicron infections also 81 experienced a 56% (95% CI: 26%, 74%, P =0.004) and 79% (95% CI: 54%, 91%, 82 P < 0.001) reduction in the risk and rate of post-acute symptoms, respectively. 83
- 84 **Conclusions and Relevance:** These findings suggest that among previously
- immunologically naïve adults, few Omicron (BA.1/BA.2) and Delta infections are
 asymptomatic, and relative to Delta, Omicron infections were less likely to seek
- healthcare and experience post-acute symptoms.

88 **III. MAIN TEXT** (2,971 of max 3,000 words)

89 Introduction

- 90 COVID-19 public health policies and control efforts must consider evolving clinical and
- 91 epidemiological features of disease.¹⁻³ Since these features can be impacted by SARS-
- 92 CoV-2 genomic changes, the World Health Organization recommends re-evaluation of
- the clinical course of COVID-19 with the arrival of new SARS-CoV-2 variants.³ In
- 94 December 2021, the B.1.1.529 (Omicron) variant of concern became the predominant
- 95 SARS-CoV-2 variant circulating in the United States (U.S.), followed by a rapid rise in
- 96 cases. By March 2022, the U.S. seroprevalence of infection-induced SARS-CoV-2
- 97 antibodies was estimated to have increased by nearly 25%,⁴ with a 35% increase
- 98 observed among unvaccinated adults.⁵
- 99 Although numerous studies have found differences in Omicron variant clinical outcomes
- 100 compared with previous variants,⁶⁻¹¹ these findings are difficult to interpret due to
- 101 changes in population immunity from natural infection and/or vaccinations.¹²⁻¹⁴ To date,
- 102 longitudinal, community-based cohort studies examining Omicron infection
- 103 characteristics have predominantly studied vaccinated cohorts.^{7,15} Yet, investigating
- 104 clinical outcomes among immunologically naïve populations remains important to
- 105 understand the consequences of SARS-CoV-2 genomic variation.
- In this study, we examined acute and post-acute (or "long") COVID-19 clinical outcomes
- 107 during a period of Omicron (BA.1/BA.2 lineages) variant predominance among a
- 108 community-based prospective cohort of immunologically naïve adults who were at high-
- risk of infection and undergoing high-resolution symptom and virologic surveillance. To
- identify differences in clinical illness, we compared outcomes with study participants
- 111 who contracted SARS-CoV-2 during a period of Delta variant predominance.

112 Methods

113 Design, Setting, and Participants

- 114 The COVID-19 Immune Protection Study (CovidIPS) is a multisite, prospective cohort
- study designed to examine SARS-CoV-2 innate and adaptive immune responses
- among immunologically naïve adults. To ensure an adequate sample size, participants

were recruited using web-based advertisements from targeted geographic locations with
high SARS-CoV-2 community transmission and suboptimal COVID-19 vaccination rates
in 8 U.S. states (AL, AZ, CA, ID, NV, OR, UT, and WA). To ensure feasibility of study
procedures, recruitment locations must have been within the service-region of a national
mobile phlebotomy company or in close-proximity to one of two research sites.
Volunteers were recruited between March 2021 and February 2022. At enrollment,

eligible volunteers were 30 to <65 years of age, without a previous history of COVID-19
vaccination or SARS-CoV-2 infection, and were deemed at high-risk for contracting
SARS-CoV-2 (supplementary methods). Volunteers were screened via an electronic
survey in English or Spanish. Eligible volunteers were contacted via telephone, with
written consent documented electronically. The Western Institutional Review Board
approved this study.

129 Data and Sample Collection

Study data were collected and managed using REDCap (Research Electronic Data 130 Capture), a secure, web-based software platform designed to support data capture for 131 research studies, hosted by the Fred Hutchinson Cancer Center.^{16,17} To confirm 132 immune status upon enrollment, participants submitted a blood sample, and SARS-133 CoV-2 receptor binding domain (RBD) IgG endpoint titers were quantified. Participants 134 who had either a positive RBD IgG or a borderline RBD IgG and positive nucleocapsid 135 IgG were excluded from the study. Following enrollment, participants completed a 136 baseline questionnaire, and began weekly "routine" procedures for 24 weeks consisting 137 of both: (i) an electronic survey to report COVID-19 symptoms, and (ii) a self-collected 138 nasal swab submitted for SARS-CoV-2 reverse transcription polymerase chain 139 reactions (RT-PCR) testing (supplementary methods). If a participant reported COVID-140 19 symptoms or had a RT-PCR-positive swab, the participant was placed on 141 "enhanced" procedures consisting of: (i) daily, electronic symptom surveys and (ii) self-142 collected nasal swabs submitted every other day, for up to 14-days. Participants who 143 were SARS-CoV-2 positive and reported symptoms (or did not complete their daily 144 symptom survey) on day 14 of enhanced procedures were sent symptom surveys for an 145 additional 14 days (*i.e.*, through day 28 post-initiation of enhanced procedures). 146

147 After 24 weeks, participants completed an end of study blood draw and questionnaire.

148 Participants were also offered an opportunity to reconsent for an additional 24-weeks of

follow-up, consisting of the same study procedures as the previous 24-weeks.

150 **Exposure ascertainment**

SARS-CoV-2 infection was defined as \geq 1 RT-PCR-positive result with an infection index date during the time periods that Delta or Omicron (BA.1/BA.2) variants represented the predominant (\geq 50%) SARS-CoV-2 variant circulating in the participant's geographic region. Weighted, regional NowCast model estimates from the U.S. Centers for Disease Control and Prevention's national genomic surveillance system were used to ascertain dates to categorize Omicron (BA.1/BA.2) versus Delta infections (supplemental methods).¹⁸

158 The infection index date was defined as the first of either the participant's symptom

159 onset or first SARS-CoV-2 RT-PCR-positive swab collection date. Symptom onset dates

were determined by participant self-report; where missing, the first date a symptom was

161 reported on surveys was used.

162 **Outcome ascertainment**

Acute COVID-19 symptoms were defined as symptoms within 28 days of the 163 participant's symptom onset date, which represents a time period frequently used to 164 demarcate the transition to post-COVID conditions.¹⁹⁻²¹ To minimize misclassification 165 due to nonspecific conditions, a window of ±14 days within the collection date of the first 166 RT-PCR positive result was used to examine COVID-19 symptoms; to be considered 167 asymptomatic, participants must have both: (i) denied symptoms in all surveys 168 submitted during this time period, and (ii) submitted at least one survey indicating they 169 did not have symptoms 7 or more days after RT-PCR testing to ensure sufficient follow 170 up.² Post-acute symptoms were defined as any symptom the participant reported as 171 172 "related to their previous COVID-19 illness" 5 weeks or more after symptom onset (or first PCR positive for asymptomatic participants); this time period was selected because 173 it was consistent with study procedures (*i.e.*, a return to weekly procedures at up to 28 174 days following enhanced procedures), and common definitions of post-COVID 175

conditions as symptoms experienced at least 4 weeks after infection.¹⁹⁻²¹ In sensitivity
analyses, we explored alternate post-acute definitions modifying this time period, the
number of surveys required with reports of post-acute symptoms, and/or post-acute
symptoms considered. Participants recorded post-acute symptoms in routine weekly
surveys until the first of either the participant's study end date or the analyses end date
(September 9, 2022).

182 Statistical Analyses

183 Risks and 95% confidence intervals (CI) of acute asymptomatic infections and postacute symptoms were estimated overall and by variant among participants 184 immunologically naïve at the time of infection; relative risks (RR) and 95% CI were 185 estimated comparing Omicron with Delta (referent) infections. Where RR could not be 186 estimated (due to zero outcomes among the referent group), absolute risk differences 187 and 95% CI were estimated. To account for differences in post-acute symptom follow up 188 time by variant, rate ratios with 95% CI were estimated using a generalized estimating 189 equation (GEE) approach with a Poisson distribution and offset term to account for 190 191 completed surveys. In these analyses, a robust "sandwich" covariance estimator with small sample size correction was used to estimate 95% CI using an exchangeable 192 correlation structure.^{22,23} These models were extended to include multivariable 193 adjustment for participant age (continuous) and gender (binary). 194

Descriptive analyses were performed to analyze the prevalence, mean number, and
 mean severity of acute or post-acute symptoms in relation to participant symptom onset.
 Exploratory multivariable analyses were also conducted to examine the relationship
 between acute illness and post-acute symptoms (supplemental methods).

Baseline and end of study self-rated overall health, memory and concentration, and ability to walk or climb stairs were compared by SARS-CoV-2 variant. For each variable, a change score analysis was performed, comparing the difference in the participant's end of study response from baseline after adjustment for their baseline score; an alpha level of <0.05 was used to denote statistical significance. In primary analyses, Omicron and Delta infections were directly compared; in secondary analyses, each variant was

compared with participants who remained naïve at the end of study survey. For

inclusion in either analysis, SARS-CoV-2-positive participants must have had ≥5 weeks

between their end of study survey and symptom onset (or first PCR-positive date for
 asymptomatic participants).

All analyses were conducted using RStudio with R version 4.2.0 (The R Foundation for Statistical Computing, Vienna, Austria).

211 **Results**

- 212 During the study period, 274 immunologically naïve participants were enrolled in the
- 213 CovidIPS cohort. Among these participants, 166 (61%) became SARS-CoV-2 RT-PCR-
- positive without a prior history of vaccination or disease; 137 (83%) and 29 (17%)
- 215 infections occurred during the Omicron- and Delta-predominant periods, respectively.
- Acute symptom data was available for 164 (99%) infections, post-acute symptom data
- was available for 150 (90%) infections, and end of study survey data ≥5-weeks post-
- infection were available for 133 (80%) participants.
- 219 Demographics of the CovidIPS cohort are compared by infection status in Supplemental
- Results Table 1, and a study flow diagram is provided in Supplemental Figure 1.

221 Acute symptoms and healthcare utilization

- Among the 164 first-time infections with acute survey data, 9 (5.5%, 95% CI: 2.5%,
- 10.2%) did not report symptoms and were classified as asymptomatic. Stratified by
- variant, 0.0% (95% CI: 0.0%, 11.9%) of Delta and 6.7% (95% CI: 3.1%, 12.3%) of
- Omicron infections were asymptomatic, representing a 6.7% (95% CI: 2.5%, 10.9%,
- P = 0.002) absolute risk reduction in symptomatic illness among Omicron infections.
- Acute symptom prevalence and severity among the 155 symptomatic infections are examined by days since onset in Figures 1 and 2, while the mean daily number of acute symptoms are examined in Supplemental Figure 2. In general, the prevalence of COVID-19 symptoms was similar by variant; however, participants with Delta infections appeared more likely to report a loss of taste or smell and rate these symptoms with a higher mean severity.

Overall, 8.5% (95% CI: 4.7%, 13.9%) of participants sought healthcare for acute symptoms, with no participants requiring emergency care or hospitalization. The *RR* of any healthcare utilization was 79% (95% CI: 43%, 92%) lower among Omicron relative to Delta infections (RR = 0.21, 95% CI: 0.08, 0.57, P=0.001). Overall, 5.5% (95% CI: 2.5%, 10.2%) of participants received a prescribed medication (supplemental results), with an 83% (95% CI: 40%, 95%, P=0.002) *RR* reduction among Omicron relative to Delta infections.

240 Post-acute symptoms

Among 150 participants with post-acute data, 123 and 27 participants were infected 241 242 during the Omicron- and Delta-predominant periods, respectively. Overall, 39 (26.0%, 95% CI: 19.2%, 33.8%) participants reported at least one symptom during the post-243 244 acute period. Stratified by variant, 21.1% (95% CI: 14.3%, 29.4%) of Omicron cases 245 and 48.1% (95% CI: 28.7%, 68.1%) of Delta cases reported post-acute symptoms, representing a 56% (95% CI: 26%, 74%) RR reduction in post-acute symptoms (RR =246 0.44, 95% CI: 0.26, 0.74; P=004) among Omicron participants. When analyzed as a 247 rate, Omicron and Delta infections experienced post-acute symptoms 4.9 (95% CI: 3.9, 248 249 5.9) per 100 person-weeks and 29.2 (95% CI: 25.4, 33.1) per 100 person-weeks, respectively, representing a rate ratio of 0.21 (95% CI: 0.09, 0.46, P<0.001) among 250 Omicron versus Delta infections. Similar rate ratio reductions were found after 251 adjustment for participant age and gender (data not shown). Results from sensitivity 252 analyses demonstrated similar RR reductions for most (5/6) modified post-acute 253 definitions (Table 1). In general, the magnitude of RR reductions among Omicron 254 participants were more pronounced under more stringent post-acute definitions; 255 however, RR estimates were imprecise. A definition examining only cognitive post-acute 256 symptoms found no difference between variants. 257

We examined mean severity of post-acute symptoms by variant and individual postacute symptom trajectories in Supplemental Figures 3 and 4, respectively. To ensure comparability, analyses were restricted to 142 (94.7%) unvaccinated participants who did not experience SARS-CoV-2 re-infection; 33 (22 Omicron, 11 Delta) reported postacute symptoms. While these analyses represent small numbers of participants, they

may suggest differences in post-acute symptom severity by strain, with Delta infections
 reporting higher mean severity and frequencies of post-acute symptoms.

Given the small number of participants with post-acute symptoms, we grouped Delta 265 and Omicron infections together to examine relationships between acute illness and 266 post-acute symptoms. Figure 3 and Supplemental Figures 5 and 6 examine the total 267 number of distinct symptoms, prevalence of acute symptoms, and symptom severity 268 269 among these participants by post-acute status, while results from exploratory multivariable analyses examining the relationship between acute and post-acute 270 outcomes are reported in Supplemental Results Table 2. In general, these analyses 271 suggest that increasing acute symptom severity, particularly during the first two weeks 272 of acute illness, is associated with higher relative odds/rates of post-acute symptoms, 273 and that prevalence of many acute symptoms was greater among participants who 274 experienced post-acute symptoms. 275

276 Changes in baseline and end of study self-rated scores

Among the 133 (23 Delta, 110 Omicron) participants with end of study data ≥5-weeks following symptom onset, no changes were detected by variant in self-rated measures for overall health, memory or concentration, or physical abilities between enrollment and end of study surveys (Figure 4). These results were similar for primary analyses comparing variants directly, and secondary analyses comparing each variant to participants who remained naïve at their end of study survey (n=90, Figure 4).

283 Discussion

In this study, we describe COVID-19 acute and post-acute outcomes in a well-284 characterized, community-based, prospective cohort of unvaccinated and previously 285 286 uninfected healthy adults at high risk of infection. Our data demonstrate that SARS-CoV-2 infections during the Omicron (BA.1/BA.2) period were associated with 287 significantly lower absolute risks of acute symptomatic infections, and significant relative 288 289 reductions in healthcare utilization for acute illness and post-acute symptoms at ≥5 weeks in comparison with Delta variant infections. While several studies have also 290 found lower acute severity of Omicron compared with Delta infections, these studies 291

have included predominantly vaccinated populations.^{7,11} To our knowledge, this is the
first study to characterize both acute and post-acute symptoms in a cohort of
immunologically naïve individuals in the era of widespread vaccination and increased
SARS-CoV-2 seroprevalence using prospective surveillance.

Defining the spectrum of COVID-19 illness for SARS-CoV-2 variants remains important to elucidate the clinical consequences of SARS-CoV-2 genomic variation.¹⁻³ For these purposes, exploring outcomes among unvaccinated and previously uninfected persons may be of particular significance for understanding the natural course of infection in the absence of pre-existing host immunity, facilitating comparisons between variants, and identifying the impact of COVID-19 among non-naïve populations, should immunity wane to levels that do not influence clinical illness.

Importantly, as COVID-19 hospitalization and mortality rates have fallen, other 303 endpoints, such as symptom prevalence and severity, have become critical to 304 305 characterize the impact of different variants. In the present study, we evaluated epidemiological characteristics of mild COVID-19 illness using a prospective cohort 306 design with frequent and high-resolution symptom and virologic surveillance. With these 307 rigorous methods, we were able to provide key insights regarding the prevalence of 308 asymptomatic infections, which are difficult to ascertain using cross-sectional designs 309 that cannot distinguish between pre-symptomatic or asymptomatic infection,² or cohorts 310 recruited at a healthcare setting, which may be increasingly unrepresentative of mild 311 disease in an era of pervasive at-home SARS-CoV-2 diagnostics.²⁴ Overall, we found 312 that the prevalence of asymptomatic infections was only 6% among all SARS-CoV-2 313 infections, with a significantly higher absolute prevalence among Omicron (7%) versus 314 Delta (0%) infections. Our estimates of asymptomatic Omicron infections were lower 315 316 when compared with a recent systematic review and meta-analysis, which also found a significantly higher proportion of asymptomatic infections among Omicron (25%) versus 317 Delta (8%) infections.²⁵ This apparent difference may reflect characteristics of our study 318 cohort, who represent previously immunologically naïve adults, 30 to 64 years of age, 319 factors also associated with a lower prevalence of asymptomatic disease.²⁵ 320

Our prospective design also enabled us to estimate risks of post-acute or "long" COVID-321 19 symptoms among a fully enumerated cohort of SARS-CoV-2 infections, which may 322 be more accurate than designs that recruit participants at healthcare settings or 323 following the development of post-acute symptoms.¹ We found that approximately one-324 quarter (26%) of participants experienced at least one post-acute symptom ≥5-weeks 325 following their infection. Our study is also among few to date that compared the risks of 326 post-acute COVID-19 symptoms by variant, and the only study (to our knowledge) that 327 compared post-acute risks among unvaccinated individuals. We found that risks of post-328 329 acute symptoms at ≥5 weeks differed significantly by variant, with approximately onefifth (21%) of Omicron infections versus nearly one-half (48%) of Delta infections 330 experiencing post-acute symptoms, representing a relative risk reduction of more than 331 50% or a rate ratio reduction of 79% among Omicron infections. These findings 332 remained robust under more stringent definitions of post-acute symptoms examining 333 symptoms at ≥8- and ≥12-weeks. Our results were also similar to results from a study of 334 vaccinated individuals, which found 59% to 77% reductions in the odds of post-acute 335 symptoms among Omicron relative to Delta infections.²⁶ 336

This study has several strengths. Our recruitment methods and prospective design 337 enabled us to ascertain participant baseline immune status with greater certainty than 338 studies using administrative data. Our study procedures also featured frequent 339 symptom and virologic surveillance with few missing data and high retention of study 340 341 participants, allowing us to characterize outcomes with greater accuracy than cohorts ascertained following infection. Further, the distribution of SARS-CoV-2 infections 342 across Delta and Omicron time periods permitted us to compare and detect significant 343 differences in variant outcomes using the same study procedures. Finally, during an era 344 of widespread infections and vaccinations, our study population of immunologically 345 naïve adults also represents a unique cohort, who at the time of the study, comprised a 346 significant proportion of the U.S. population, yet remain underrepresented in scientific 347 research. 348

Our study also has several limitations. We did not sequence viral samples and used
 U.S. regional prevalence data to classify variants for our SARS-CoV-2 infections. While

this approach is similar to methods in previous studies,^{7,26} it is possible that variants
were misclassified. Due to the prospective nature of our study and our unique study
cohort, our sample size was also smaller in comparison with studies using
administrative data.

355 In conclusion, we demonstrate that among a community-based cohort of immunologically naïve adults, SARS-CoV-2 infections during Omicron (BA.1/BA.2) and 356 Delta predominant periods were associated with few asymptomatic cases of COVID-19 357 illness, and that Omicron infections were less likely to seek healthcare for acute 358 359 symptoms and more than half as likely to experience post-acute symptoms relative to Delta infections. Continued study and comparisons of clinical illness from SARS-CoV-2 360 variants are critical to understand the implications of SARS-CoV-2 genomic variation 361 362 and must be considered with regard to host immune status.

363 Acknowledgments

364 Funding

The current work was funded by the NIH NIAID under awards AI142742 (Cooperative Centers for Human Immunology, CCHI) (S.C.), and a supplement to NIH AI142742. This work was additionally supported in part by LJI Institutional Funds, and the NIAID

³⁶⁸ under K08 award Al135078 (J.M.D.).

369 Conflicts of Interest

MKD has received research support from St. Luke's Wood River Foundation. AW 370 served as an advisory board member for Kyorin Pharmaceutical, and received research 371 support from GSK, Vir Biotechnology, Pfizer, Allovir, Ansun Biopharma and Amazon (all 372 for work outside this study). AH, DH, and FS are employed by and hold equity in 373 Amazon. JB received research support from GSK and IgM Biosciences (all for work 374 outside this study). MB served as a consultant for Vir Biotechnology, Merck, and 375 Moderna, and received research support from GSK, Vir Biotechnology, Merck, 376 Ridgeback, Amazon, and Regeneron. SC has consulted for GSK, JP Morgan, Citi, 377 Morgan Stanley, Avalia NZ, Nutcracker Therapeutics, University of California, California 378 State Universities, United Airlines, Adagio, and Roche. 379

It is made available under a CC-BY-NC-ND 4.0 International license .

380 IV. REFERENCES

Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post-acute COVID-19 syndrome
 symptoms at different follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect*.
 May 2022;28(5):657-666. doi:10.1016/j.cmi.2022.01.014

Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic
 review and meta-analysis. *Proc Natl Acad Sci U S A*. Aug 24 2021;118(34)doi:10.1073/pnas.2109229118

World Health Organization. World Health Organization, WHO R&D Blueprint COVID-19 new
 variants: Knowledge gaps and research. Accessed August 11, 2022.

388 <u>https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-</u>
 389 <u>report 20.03.2012.pdf?sfvrsn=5ac5785_3&download=true</u>

Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies
 - United States, September 2021-February 2022. *MMWR Morb Mortal Wkly Rep*. Apr 29
 2022;71(17):606-608. doi:10.15585/mmwr.mm7117e3

3935.Alejo JL, Chiang TPY, Mitchell J, et al. Incidence of SARS-CoV-2 infection among unvaccinated US394adults during the Omicron wave. J Intern Med. Aug 10 2022;doi:10.1111/joim.13555

Bouton TC, Atarere J, Turcinovic J, et al. Viral dynamics of Omicron and Delta SARS-CoV-2
variants with implications for timing of release from isolation: a longitudinal cohort study. *medRxiv*. Apr
5 2022;doi:10.1101/2022.04.04.22273429

 Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *Lancet*. Apr 7 2022;doi:10.1016/S0140-6736(22)00327-0

Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough,
 Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019
 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
 Am J Pathol. Apr 2022;192(4):642-652. doi:10.1016/j.ajpath.2022.01.007

Fall A, Eldesouki RE, Sachithanandham J, et al. A Quick Displacement of the SARS-CoV-2 variant
Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and
Comparable Upper Respiratory Viral Loads. *medRxiv*. Jan 28 2022;doi:10.1101/2022.01.26.22269927

Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA
vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
prospective observational study. *BMJ*. Mar 9 2022;376:e069761. doi:10.1136/bmj-2021-069761

11. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
cohort study. *Lancet*. Apr 2 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7

415 12. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2
416 Omicron Variant. *N Engl J Med*. Feb 17 2022;386(7):e14. doi:10.1056/NEJMp2119682

417 13. Strasser Z, Hadavand A, Murphy S, Estiri H. SARS-CoV-2 Omicron Variant is as Deadly as Previous
418 Waves After Adjusting for Vaccinations, Demographics, and Comorbidities. *ResearchSquare Preprint*.
419 2022;doi:<u>https://doi.org/10.21203/rs.3.rs-1601788/v1</u>

420 14. Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? *Nat Rev*421 *Immunol*. Feb 2022;22(2):69-71. doi:10.1038/s41577-022-00678-4

Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity of the SARSCoV-2 Omicron variant. *medRxiv*. 2022:2022.01.13.22269257. doi:10.1101/2022.01.13.22269257

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
community of software platform partners. *Journal of Biomedical Informatics*. 2019/07/01/
2019;95:103208. doi:<u>https://doi.org/10.1016/j.jbi.2019.103208</u>

427 17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 428 (REDCap)—A metadata-driven methodology and workflow process for providing translational research

429 informatics support. *Journal of Biomedical Informatics*. 2009/04/01/2009;42(2):377-381.
 430 doi:<u>https://doi.org/10.1016/j.jbi.2008.08.010</u>

431 18. Centers for Disease Control and Prevention. COVID Data Tracker: Nowcast. Atlanta, GA: US

432 Department of Health and Human Services. Accessed September 9,, 2022. <u>https://covid.cdc.gov/covid-</u>
 433 <u>data-tracker/#variant-proportions</u>

434 19. Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. Accessed
 435 September 12,, 2022. <u>https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</u>

Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post
COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis*. Apr 16
2022;doi:10.1093/infdis/jiac136

439 21. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7
440 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.

Fay MP, Graubard Bl. Small-sample adjustments for Wald-type tests using sandwich estimators. *Biometrics*. Dec 2001;57(4):1198-206. doi:10.1111/j.0006-341x.2001.01198.x

44323.Kim J, Troxel AB, Halpern SD, et al. Analysis of multicenter clinical trials with very low event444rates. *Trials*. Nov 9 2020;21(1):917. doi:10.1186/s13063-020-04801-5

445 24. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. *MMWR Morb Mortal Wkly Rep*. Apr 1 2022;71(13):489-494.

447 doi:10.15585/mmwr.mm7113e1

Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic infection and
nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis. *J Med Virol*. Aug 12 2022;doi:10.1002/jmv.28066

451 26. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta 452 versus omicron variants of SARS-CoV-2. *The Lancet*. 2022;399(10343):2263-2264. doi:10.1016/S0140-453 6736(22)00941-2

454

Definition	# Weeks	# Surveys with symptoms	Symptoms	Risk - Omicron (BA.1/BA.2) % (95% CI)	Risk – Delta (B.1.617.2) % (95% Cl)	Risk Ratio (95% Cl)	P-value
1*	≥5	≥1	Any	21% (14%, 29%)	48% (29%, 68%)	0.4 (0.3, 0.7)	0.004
2	≥5	≥1	Cognitive ⁺ only	12% (7%, 19%)	15% (4%, 34%)	0.8 (0.3, 2.3)	0.7
3	≥5	≥2	Any	13% (8%, 20%)	41% (22%, 61%)	0.3 (0.2, 0.6)	<0.001
4	≥8	≥1	Any	20% (13%, 28%)	44% (25%, 65%)	0.4 (0.3, 0.8)	0.008
5	≥8	≥2	Any	8% (4%, 14%)	37% (19%, 58%)	0.2 (0.1, 0.5)	<0.001
6	≥12	≥1	Any	10% (5%, 17%)	42% (23%, 63%)	0.2 (0.1, 0.5)	<0.001
7	≥12	≥2	Any	4% (1%, 9%)	35% (17%, 56%)	0.1 (0.0, 0.3)	<0.001

456 **Table 1.** Modified definitions, risks, and risk ratios (*RR*) of post-acute symptoms comparing Omicron versus Delta (referent) variant infections.

457 *Definition 1: used for primary analyses; *Cognitive symptoms defined as reports of any of the following symptoms: changes in mood, confusion, extreme fatigue, inability to concentrate, insomnia,

458 or memory lapses

459

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Prevalence of acute COVID-19 symptoms by variant. Data represents the percentage of symptoms reported among participants who submitted a survey
 each day; only symptomatic persons were included (n=155). *Abbreviations*: EET: eyes, ears, and throat; GI: gastrointestinal.






Figure 2. Mean severity of acute COVID-19 symptoms by variant. Data represents the mean severity rating for each symptom among participants who submitted a survey each day; only symptomatic persons were included (n=155). *Abbreviations*: EET: eyes, ears, and throat; GI: gastrointestinal.




medRxiv preprint doi: https://doi.org/10.1101/2022.11.13.22282222; this version posted November 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3. Histogram of distinct acute symptoms reported by week and post-acute symptom status; only unvaccinated and persons with one episode of SARS CoV-2 were included (n=142).



- **Figure 4.** Comparison of participant enrollment and end of study self-rated scores for
- health (highest health = 5), concentration & memory (highest abilities = 4), and ability to
- 471 walk & climb stairs (highest abilities = 4). Dots represent the proportion of participants
- by variant/SARS-CoV-2 status whose responses align with a given survey pattern.
- Areas shaded in red represent a decline in health scores at the end of study survey,
- while shaded blue areas represent a positive health gain at the end of study.



Proportion • 0.2 • 0.4 • 0.6 • 0.8